CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • April 25th, 2019 • Mateon Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of April 17, 2019 (this “Agreement”), is entered into by and among Mateon Therapeutics, Inc., a Delaware corporation (the “Company”), Oncotelic, Inc., a Delaware corporation (“Oncotelic”), American Stock Transfer & Trust Company, LLC, a New York limited liability trust company (the “Rights Agent”) and initial CVR Registrar (as defined herein), and Matthew M. Loar, acting solely in his capacity as representative of the Holders (as defined herein) (the “Holder Representative”).
